Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

François-Clément Bidard,Céline Callens,Florence Dalenc,Barbara Pistilli,Thibault De La Motte Rouge,Florian Clatot,Véronique Dhondt,Luis Teixeira,Helene Vegas,S Everhard,Jérome Lemonnier,Ivan Bièche,Anne Pradines,Jean Francois Paitel,Dominique Spaeth,I. Moullet,Jean-Yves Pierga,Frédérique Berger,Anne Claire Hardy-Bessard,Thomas Bachelot

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

2020

1010Background: The question of which is the best endocrine partner to CDK4/6 inhibitors in first line for ER+ HER2- metastatic breast cancer (MBC) remains open. ESR1 mutations might be of paramoun...

Keywords:

Physical therapy
Oncology
Palbociclib
Internal medicine
first line
exploratory analysis
Medicine
Endocrine system
Pathology
Estrogen receptor alpha
Metastatic breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations